Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

The Quinism Foundation Shares its Concerns with Theranexus Regarding its Drug Candidate THN201
  • USA - English

Mefloquine, a Component of TNH201, May Cause Neuropsychiatric Adverse Effects Including Cognitive Dysfunction and Nightmares That May Last Years After Use


News provided by

The Quinism Foundation

Oct 08, 2018, 03:00 ET

Share this article

Share toX

Share this article

Share toX

WHITE RIVER JUNCTION, Vt., Oct. 8, 2018 /PRNewswire-PRWeb/ -- The Quinism Foundation has sent correspondence to Mathieu Charvériat, Scientific Director and Deputy Chief Executive Officer of Paris-based Theranexus, sharing its concerns regarding its drug candidate THN201, a combination of donepezil and mefloquine, which aims to treat neurocognitive disorders in Alzheimer's disease.

"Adding mefloquine to an Alzheimer's drug is like adding gasoline to a fire extinguisher," said Remington Nevin, MD, MPH, DrPH, executive director of The Quinism Foundation. "This effort at drug repurposing raises significant safety concerns, and particularly in light of existing warnings for use of mefloquine, should attract further scrutiny by drug regulators."

According to European, U.S., and Canadian drug regulators, mefloquine may cause neuropsychiatric adverse effects that may persist years after use [1]. Drug regulators at the European Medicines Agency (EMA) have concluded that there is sufficient evidence "supporting a causal relationship between mefloquine and the occurrence of long lasting and even persistent neuropsychiatric effects" and have speculated that these are due to "permanent brain damage." The EMA has noted that no risk factors could be identified for this effect, and that for this reason "only the advice—to stop taking mefloquine if neuropsychiatric reactions or changes to their mental state occur can be given as a precautionary measure." [2]

"The EMA has since required the mefloquine product documentation be updated with a boxed warning," explained Dr. Nevin, "cautioning that when used for the prevention of malaria, mefloquine is to be discontinued at the onset of symptoms of insomnia, abnormal dreams, nightmares, acute anxiety, depression, restlessness or confusion, which, in the EMA's language, 'have to be regarded as prodromal for a more serious event'."

"The 'more serious event' that may occur with use of mefloquine can include lasting and disabling nightmares and neurocognitive impairment," said Dr. Nevin.

In a double-blinded randomized trial of mefloquine 250 mg weekly versus chloroquine, poor concentration was reported by 5% of mefloquine users, versus only 1% of chloroquine users [3]. In a double-blinded randomized trial of mefloquine 250 mg weekly versus atovaquone-proguanil, concentration impairment requiring discontinuation of the study drug was reported in 0.6% of mefloquine users, versus 0% of atovaquone-proguanil users [4]. In a follow-up study of those who had reported cognitive dysfunction with use of mefloquine, fully one-third reported this symptom lasting over three years after use [5].

Recent research also confirms that nightmares and other abnormal dreams affect nearly 1 in 7 of those exposed to mefloquine for the prevention of malaria [4], and that more than 1 in 5 of those who complain of nightmares report this symptom lasting as long as three years after use [5].

"The last thing a family member would want is for their loved one to suffer the remainder of their lifetime from horrific nightmares and worsened cognitive impairment as a result of their use of a study drug," said Dr. Nevin. "Yet this is precisely what may happen with attempts to use mefloquine to treat Alzheimer's disease."

In its correspondence, The Quinism Foundation encouraged Theranexus to immediately review its clinical protocols for the testing of THN201 to ensure that possible adverse effects from mefloquine will be properly recognized and reported.

"We would encourage you to specifically inquire of your subjects prior to every dose of the study drug if they are experiencing symptoms of abnormal dreams, nightmares, insomnia, anxiety, depression, restlessness, or confusion," wrote Dr. Nevin. "If your subjects cannot respond reliably to this question, the drug should be immediately discontinued. If, for whatever reason, they report these or other psychiatric symptoms, these should be considered prodromal to a more serious event, and the drug should be similarly immediately discontinued".

"While we recognize that subjects enrolled in a trial for Alzheimer's disease may already be experiencing such symptoms," wrote Dr. Nevin, "it is this very fact that will typically preclude their safe use of the medication. Mefloquine is, notably, contraindicated for use in chemoprophylaxis among those with pre-existing psychiatric disturbances, including Alzheimer's disease, among whom the reliable recognition of prodromal symptoms poses significant challenges."

About The Quinism Foundation

The Quinism Foundation, founded in January 2018, in White River Junction, Vermont, promotes and supports education and research on chronic quinoline encephalopathy, a disease caused by poisoning of the brain and brainstem by quinoline drugs, including mefloquine and tafenoquine.

Dr. Nevin is a board-certified occupational medicine and preventive medicine physician and former U.S. Army medical officer and epidemiologist. He is author of more than 30 scientific publications on malaria and the quinoline antimalarials, including "A serious nightmare: psychiatric and neurologic adverse reactions to mefloquine are serious adverse reactions," published in the journal Pharmacology Research and Perspectives (https://doi.org/10.1002/prp2.328).

1. Nevin RL. Implications of Changes to the Mefloquine Product Monograph. Canadian Journal of Hospital Pharmacy. 2017;70(4):323-324.
2. European Medicines Agency. Updated PRAC Rapporteur Assessment Report on the Signal of Permanent Neurologic (Vestibular) Disorders with Mefloquine. EMA/63963/2014. January 31, 2014.
3. Boudreau E, Schuster B, Sanchez J, et al. Tolerability of prophylactic Lariam regimens. Tropical Medicine and Parasitology. 1993;44(3):257-265.
4. Overbosch D, Schilthuis H, Bienzle U, et al. Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study. Clinical Infectious Diseases. 2001;33(7):1015-1021.
5. Ringqvist Å, Bech P, Glenthøj B, et al. Acute and long-term psychiatric side effects of mefloquine: A follow-up on Danish adverse event reports. Travel Medicine and Infectious Disease. 2015;13(1):80–88.
6. Tickell-Painter M, Maayan N, Saunders R, et al. Mefloquine for preventing malaria during travel to endemic areas. The Cochrane Database of Systematic Reviews. 2017;10(10):CD006491.

SOURCE The Quinism Foundation

Related Links

http://quinism.org

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.